Phase II study of crizotinib in East Asian patients with ROS1-positive advanced NSCLC

“Crizotinib (Xalkori) induced a nearly 72% overall response rate and a median progression-free survival of almost 16 months in a single-arm phase II trial of 127 patients with ROS1-positive advanced non–small cell lung cancer (NSCLC).”

read full article here

Published by

Lysa B

mom, wife, daughter, advocate, and stage IV lung cancer survivor.